二甲双胍对2型糖尿病患者的肾脏保护作用
这项回顾性观察性多中心队列研究纳入7家医院316693例2型糖尿病患者,经倾向性评分及年龄、性别、医疗年度、基线eGFR、尿蛋白、HbA1c匹配后,二甲双胍组与非二甲双胍组各13096例。二甲双胍组血清肌酐翻倍、eGFR≤15 mL/min/1.73 m²及终末期肾病的发生率均低于非二甲双胍组。
要点
- 二甲双胍组血清肌酐翻倍风险低于非二甲双胍组(HR 0.71;95%CI 0.65-0.77)。
- 二甲双胍组eGFR≤15 mL/min/1.73 m²风险低于非二甲双胍组(HR 0.61;95%CI 0.53-0.71)。
- 二甲双胍组终末期肾病风险低于非二甲双胍组(HR 0.55;95%CI 0.47-0.66)。
核心结论
- 二甲双胍降低了2型糖尿病患者肾功能恶化的风险。
研究设计与样本
- 回顾性观察性多中心队列研究,纳入7家医院316693例2型糖尿病患者。
- 按年龄、性别、医疗年度、基线eGFR、尿蛋白(试纸法)、HbA1c及倾向性评分匹配后,二甲双胍组13096例、非二甲双胍组13096例。
- 主要结局为血清肌酐翻倍、eGFR≤15 mL/min/1.73 m²和终末期肾病(ESKD)。
主要发现
- 多变量logistic回归分析显示,二甲双胍组血清肌酐翻倍发生率低于非二甲双胍组(HR 0.71;95%CI 0.65-0.77)。
- 二甲双胍组eGFR≤15 mL/min/1.73 m²发生率低于非二甲双胍组(HR 0.61;95%CI 0.53-0.71)。
- 二甲双胍组ESKD发生率低于非二甲双胍组(HR 0.55;95%CI 0.47-0.66)。
- 亚组分析显示,在不同肾功能患者中肾脏保护作用一致;在考虑年龄、性别、合并症和用药等因素的亚组分析中,几乎全部亚组均显示二甲双胍组肾功能恶化更慢。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inhibiting the development and progression of diabetic kidney disease (DKD) is an important issue, but the renoprotective effect of metformin is still controversial. OBJECTIVE: To assess the renoprotective effect of metformin in patients with type 2 diabetes. METHODS: This retrospective observational multicenter cohort study included 316 693 patients with type 2 diabetes from 7 hospitals. After matching for age, gender, medical year, baseline estimated glomerular filtration rate (eGFR), urine protein (dipstick), glycated hemoglobin (HbA1c) and propensity score; a total of 13 096 metformin and 13 096 non-metformin patients were included. The main results were doubling of serum creatinine, eGFR ≤ 15 mL/min/1.73 m2 and end-stage kidney disease (ESKD). RESULTS: After conducting a multivariable logistic regression analysis on the variables, the metformin group was revealed to have better renal outcomes than the non-metformin group, including a lower incidence of doubling of serum creatinine (hazard ratio [HR], 0.71; 95% CI, 0.65-0.77), eGFR ≤ 15 mL/min/1.73 m2 (HR 0.61; 95% CI, 0.53-0.71), and ESKD (HR 0.55; 95% CI, 0.47-0.66). The subgroup analyses revealed a consistent renoprotective effect across patients with various renal functions. Furthermore, when considering factors such as age, sex, comorbidities, and medications in subgroup analyses, it consistently showed that the metformin group experienced a slower deterioration in renal function across nearly all patient subgroups. CONCLUSION: Metformin decreased the risk of renal function deterioration.
引用
- Wang HH, Lin SH, Hung SY, et al. Renal Protective Effect of Metformin in Type 2 Diabetes Patients. J Clin Endocrinol Metab. 2025. PMID: 38986038. doi:10.1210/clinem/dgae477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。